Congenital Nephrotic Syndrome Medical Services in China

Congenital Nephrotic Syndrome (CNS) is a rare, genetically driven kidney disorder presenting within the first three months of life—typically before birth or in the neonatal period. It is characterized by massive proteinuria, severe hypoalbuminemia, hyperlipidemia, and generalized edema, resulting from structural and functional abnormalities in the glomerular filtration barrier, particularly involving podocyte slit diaphragm proteins. The most common genetic cause is autosomal recessive mutations in the NPHS1 gene encoding nephrin, accounting for ~80% of Finnish-type CNS; other implicated genes include NPHS2 (podocin), WT1, LAMB2, and PLCE1. Pathogenesis centers on disrupted podocyte architecture and signaling, leading to loss of size- and charge-selective filtration, permitting uncontrolled leakage of plasma proteins—especially albumin—into the urine. This triggers compensatory hepatic synthesis of lipoproteins and acute-phase reactants, perpetuating edema, thrombotic risk, infection susceptibility, and growth failure. Epidemiologically, CNS is exceedingly rare, with an estimated incidence of 1–3 per 100,000 live births globally; it is markedly higher in Finland (1:8,200) due to a founder NPHS1 mutation. Risk factors are predominantly genetic—consanguinity increases autosomal recessive transmission risk—and prenatal indicators such as elevated maternal alpha-fetoprotein, placental enlargement (>25% of birth weight), and fetal ascites may raise suspicion. Without intervention, CNS carries high mortality in infancy due to sepsis, thromboembolism, malnutrition, and end-stage kidney disease (ESKD). Quality of life is profoundly impacted: affected infants require intensive nutritional support, frequent albumin infusions, anticoagulation, immunosuppression (in select non-genetic or atypical cases), and early nephrectomy followed by dialysis or transplantation. Caregivers face immense psychosocial, financial, and logistical burdens—including prolonged hospitalizations, home nursing, and lifelong immunosuppressive management post-transplant. Even with successful kidney transplantation, recurrence is rare in monogenic CNS but long-term outcomes depend on timing of transplant, infection control, and neurodevelopmental surveillance. Early molecular diagnosis via genetic testing (e.g., targeted NGS panels) is critical to guide prognosis, avoid ineffective immunosuppression, and enable family counseling and prenatal testing in subsequent pregnancies.

Congenital Nephrotic Syndrome (CNS) is a rare, autosomal recessive disorder typically presenting within the first three months of life with massive proteinuria, hypoalbuminemia, hyperlipidemia, and severe edema. The most common genetic cause is mutations in the NPHS1 gene encoding nephrin, leading to structural and functional disruption of the glomerular slit diaphragm. Less frequent etiologies include mutations in NPHS2 (podocin), WT1, LAMB2, and PLCE1. Early diagnosis—via urinary protein-to-creatinine ratio (>2–3 mg/mg), serum albumin (<25 g/L), lipid profile, and confirmatory genetic testing—is critical to guide management and prognostication. Treatment is multidisciplinary, involving pediatric nephrology, genetics, nutrition, and transplant services, and must be initiated promptly to mitigate complications including infection, thrombosis, growth failure, and end-stage kidney disease (ESKD).

Conservative treatment forms the cornerstone of early CNS management and aims to stabilize physiology while preserving residual renal function. Strict sodium and fluid restriction (typically 1–2 mEq/kg/day Na⁺ and 60–80 mL/kg/day fluids) is essential to control edema and prevent pulmonary congestion. Albumin infusions (e.g., 1 g/kg IV every other day or weekly, titrated to clinical response) may transiently improve oncotic pressure and reduce ascites/pleural effusions but do not alter disease progression and carry risks of volume overload and allergic reactions. Anticoagulation (e.g., low-molecular-weight heparin at prophylactic doses) is indicated in patients with serum albumin <20 g/L due to high thrombotic risk from loss of antithrombin III and other anticoagulant proteins. Aggressive nutritional support—including high-calorie (120–150 kcal/kg/day), high-protein (3–4 g/kg/day) feeds supplemented with medium-chain triglycerides (to bypass lymphatic protein loss)—is vital to counteract catabolism and promote neurodevelopmental outcomes. Regular monitoring of serum calcium, vitamin D, thyroid hormones, and iron stores is mandatory given frequent deficiencies secondary to urinary losses.

Pharmacologic therapy has limited efficacy in genetically mediated CNS. Corticosteroids and conventional immunosuppressants (e.g., cyclophosphamide, calcineurin inhibitors) are ineffective in NPHS1- and NPHS2-related disease and are not recommended outside of rare, atypical presentations with possible immune-mediated components. However, in patients with WT1-associated CNS (e.g., Denys-Drash syndrome), tumor surveillance and early gonadectomy may be indicated due to gonadoblastoma risk. Emerging therapies under investigation include chaperone molecules targeting misfolded nephrin mutants and antisense oligonucleotides for specific splice-site variants, though none are yet approved for clinical use. ACE inhibitors or ARBs are generally avoided in infancy due to hemodynamic instability and lack of proven renoprotection in this setting; their use remains controversial and should only occur in older, stable children with preserved GFR and careful BP monitoring.

Surgical intervention is definitive for most infants with CNS. Bilateral nephrectomy—performed laparoscopically or open between 3–12 months of age—is increasingly adopted prior to kidney transplantation to eliminate persistent proteinuria, reduce infection burden (e.g., recurrent peritonitis from ascites), decrease thromboembolic risk, and improve nutritional status and growth velocity. Post-nephrectomy, patients transition to maintenance dialysis (peritoneal dialysis preferred in infants due to cardiovascular tolerance and technical feasibility) until transplantation. Kidney transplantation remains the only curative option, with excellent long-term graft survival (>90% at 5 years) when performed after nephrectomy. Recurrence of nephrotic syndrome post-transplant is exceedingly rare in monogenic CNS, distinguishing it from primary focal segmental glomerulosclerosis. Preemptive transplantation—without interim dialysis—is not advised due to poor pretransplant nutritional status and high perioperative morbidity.

China offers distinct advantages in the comprehensive management of CNS. First, national newborn screening programs for hereditary kidney diseases—though still expanding—have enabled earlier identification through targeted gene panels (e.g., NPHS1/NPHS2/WL1 sequencing) available at tertiary centers such as Peking University First Hospital and Shanghai Children’s Medical Center. Second, China’s robust organ allocation system, integrated with the China Organ Transplant Response System (COTRS), ensures equitable access to deceased-donor kidneys, with median wait times for pediatric recipients now under 18 months—comparable to Western benchmarks. Third, Chinese centers have pioneered standardized protocols for infant nephrectomy and peritoneal dialysis catheter placement, achieving >95% technical success rates and <5% major complication incidence. Fourth, cost-effectiveness is notable: government-subsidized biologics (e.g., IVIG for infection prophylaxis), domestically manufactured recombinant erythropoietin, and tiered insurance coverage (including the National Reimbursement Drug List) significantly reduce out-of-pocket burdens. Finally, multidisciplinary CNS clinics—offering integrated genetic counseling, psychosocial support, and telehealth follow-up—have demonstrated improved adherence and reduced hospitalization frequency by 35% in cohort studies.

Recovery and long-term care require lifelong vigilance. Post-transplant, patients need meticulous immunosuppression management (tacrolimus ± mycophenolate mofetil), regular monitoring of trough levels, renal function, and infection markers (CMV, EBV). Growth, bone health, and neurocognitive development must be tracked annually using WHO growth standards and validated developmental tools. Vaccination schedules should be optimized pre-transplant (e.g., pneumococcal, meningococcal, varicella) and adjusted post-transplant per KDIGO guidelines. Families benefit from structured education on recognizing rejection signs (e.g., decreased urine output, fever, graft tenderness), managing dietary sodium, and adhering to medication regimens. Psychosocial support—including peer mentoring networks and school reintegration planning—is integral to quality-of-life preservation. With timely nephrectomy, well-timed transplantation, and coordinated care, over 85% of Chinese children with CNS achieve normal schooling, social integration, and reproductive potential in adulthood—underscoring that CNS, while severe, is a manageable chronic condition rather than a uniformly fatal diagnosis.